Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Whitehawk Therapeutics (Nasdaq: WHWK), a company focused on developing advanced ADC cancer treatments, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The conference is scheduled for July 29-30, 2025, where the company's management will present their developments in oncology therapeutics and ADC technology.
Whitehawk Therapeutics (Nasdaq: WHWK), un'azienda specializzata nello sviluppo di trattamenti avanzati con ADC per il cancro, ha annunciato la sua partecipazione al prossimo BTIG Virtual Biotechnology Conference. La conferenza si terrà il 29-30 luglio 2025, durante la quale il management dell'azienda presenterà i progressi nelle terapie oncologiche e nella tecnologia ADC.
Whitehawk Therapeutics (Nasdaq: WHWK), una empresa centrada en el desarrollo de tratamientos avanzados con ADC para el cáncer, ha anunciado su participación en la próxima Conferencia Virtual de Biotecnología BTIG. La conferencia está programada para el 29-30 de julio de 2025, donde la dirección de la compañía presentará sus avances en terapias oncológicas y tecnología ADC.
Whitehawk Therapeutics (나스닥: WHWK)는 첨단 ADC 암 치료제 개발에 주력하는 기업으로, 다가오는 BTIG 가상 생명공학 컨퍼런스에 참여한다고 발표했습니다. 이 컨퍼런스는 2025년 7월 29-30일에 개최되며, 회사 경영진이 종양학 치료제 및 ADC 기술의 발전 사항을 발표할 예정입니다.
Whitehawk Therapeutics (Nasdaq : WHWK), une société spécialisée dans le développement de traitements avancés par ADC contre le cancer, a annoncé sa participation à la prochaine Conférence virtuelle BTIG sur la biotechnologie. La conférence est prévue les 29 et 30 juillet 2025, où la direction présentera ses avancées en thérapeutique oncologique et en technologie ADC.
Whitehawk Therapeutics (Nasdaq: WHWK), ein Unternehmen, das sich auf die Entwicklung fortschrittlicher ADC-Krebsbehandlungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden BTIG Virtual Biotechnology Conference angekündigt. Die Konferenz findet am 29. bis 30. Juli 2025 statt, bei der das Management des Unternehmens seine Fortschritte in der Onkologie-Therapie und ADC-Technologie vorstellen wird.
- None.
- None.
About Whitehawk Therapeutics
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-participate-in-the-btig-virtual-biotechnology-conference-302509852.html
SOURCE Whitehawk Therapeutics, Inc.
FAQ
When is Whitehawk Therapeutics (WHWK) presenting at the BTIG Virtual Biotechnology Conference?
What is Whitehawk Therapeutics' (WHWK) main business focus?
How can investors access Whitehawk Therapeutics' (WHWK) BTIG conference presentation?
Where is Whitehawk Therapeutics (WHWK) headquartered?
